Intuitive Surgical stock faces a return gap as volatility stays high

Published on 11/10/2026 at 13:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Intuitive Surgical stock has delivered weaker long-term returns than the S&P 500 while exposing investors to larger swings. Pricing and legal risks remain.

Return, volatility and next catalysts

Intuitive Surgical delivered lower annualized returns than the S&P 500 over the five years through November 9, 2026, while showing much higher volatility.
Pricing actions and a pending litigation settlement remain key factors for the da Vinci business.
The January 2027 report is expected to update the company's long-term soft-tissue surgery opportunity.

Intuitive Surgical, US46120E6023, Illustration mit AI erstellt.

Intuitive Surgical stock traded at 410.75 euros on Lang & Schwarz at 13:16 CET on Tuesday, November 10, 2026. The latest investor focus is shifting from quarterly growth alone to whether the surgical-robotics specialist is compensating shareholders for elevated volatility.

In an analysis published Tuesday, November 10, Trefis compared Intuitive Surgical with the S&P 500 over the five years from November 1, 2021, through November 9, 2026. The company returned 5.3% a year, versus 11.9% for the index, while annual volatility reached 34.9%, compared with 17.1% for the benchmark.

Higher swings, weaker compensation

The return difference was accompanied by a weaker return-to-volatility ratio. Trefis calculated a ratio of 0.152 for Intuitive Surgical, against 0.696 for the S&P 500, indicating less compensation for each unit of fluctuation during the period.

The shorter-term comparison also points to a stock driven by company-specific factors. Over the year through November 9, Intuitive Surgical recorded volatility of 35.6%, versus 13.7% for the S&P 500. Its beta was 0.93 and its correlation with the index was 0.36, suggesting that broad market moves explain only part of the share-price swings.

Trefis also found that the stock captured 67% of the average daily gain of the S&P 500 while falling 93% as much as the index on an average down day. For investors already exposed to healthcare or procedure-volume trends, the analysis therefore frames Intuitive Surgical as an additional concentration rather than a broad source of diversification.

Pricing and legal issues remain

The operating outlook includes both growth opportunities and pressure on recurring economics. Management expects pricing actions, including a policy-driven price cut in China, to reduce da Vinci instrument and accessory revenue per procedure by 3% to 5% once fully implemented, assuming procedure volume and product mix remain unchanged.

The company has also agreed to a 450 million US dollar settlement in a class action brought by US customers over third-party remanufacturing of da Vinci instruments and third-party servicing of da Vinci systems. Court approval is still pending, and management does not expect a decision until 2027, according to the Trefis analysis. In fiscal third-quarter 2026, da Vinci procedures grew 10% in the United States and 20% outside the country, highlighting the different pace of regional demand.

January brings the next test

Intuitive Surgical is expected to report again in January 2027. Management plans to update its estimate of the long-term opportunity in soft-tissue surgery at that report, making US da Vinci procedure growth a central operating indicator for investors.

The S&P 500 market reports provide the broader US equity-market context for assessing the stock's relative performance.

More news and analyses on Intuitive Surgical stock